Top Tech Companies (2,070)
Don't see your company?
Create a company profile
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better went public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the fall of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies. Better Therapeutics operates as a fully distributed company combining remote work with periodic team and all-hands in-person meetings. We are headquartered in San Francisco, CA and have employees located in 15 states across the country.
Podimetrics is a virtual care management company dedicated to preventing costly and deadly diabetic amputations. We provide high-risk patients our FDA-cleared SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address any concerning findings. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients, and allows clinicians to achieve unparalleled outcomes - keeping vulnerable patients healthy at home and saving limbs, lives, and money. Founded in 2011 by a physician and engineers from MIT and Harvard, Podimetrics is headquartered in Somerville, MA and backed by Norwich Ventures, Scientific Health Development, Polaris Partners, and Rock Health. For more information, go to www.podimetrics.com or follow us on Twitter @podimetrics.
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
At Biomason, our mission is to lead the global transition to planet-friendly construction. We are eliminating the need to emit carbon in cement production—curing the disease instead of treating the symptoms. Biomason biocement® will reduce 25% of carbon emission from the global concrete industry by 2030.
A Mosaic company. Our diverse portfolio of products is backed by science and used worldwide to enhance yields, improve nutrient use efficiency, disease defense, biocontrol and abiotic stress. We’re committed to developing new soil health solutions that will provide advanced crop nutrition to customers around the globe and continue to help the world grow the food it needs.
OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds.
Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.
The Life Sciences business of Truven Health Analytics (www.truvenhealth.com/life-sciences) is a trusted, full service market access, stakeholder management, and health economics and outcomes research (HEOR) consultancy serving the global pharmaceutical, medical device and biotech industry. With the 2014 acquisition of Heartbeat Experts (www.heartbeatexperts.com) into our Life Sciences business, we offer the leading KOL and market access stakeholder identification, profiling, mapping and engagement solutions. Truven Health Life Sciences enables our 150+ customers to effectively reach out to the right people with the right scientific evidence to demonstrate product value – anywhere in the world. (www.truvenhealth.com/life-science)
VisionGate, Inc., is a breakthrough liquid-biopsy technology company, leading the battle against lung cancer through early detection technology with a simple, non-intrusive sputum test. The foundation for our diagnostics capability is the proprietary Cell-CT™ 3-Dimensional Cell Imaging and Analysis platform. The Cell-CT platform, using a process called optical computed tomography (CT), produces 3D images of individual cells with the ability to morphologically recognize over 700 structural biomarkers of normal and abnormal cells. The Cell-CT platform can process any liquid biopsy specimen and therefore has potential applicability to detect a wide range of different cancers and cancer biosignatures that could aid in identifying potential treatments using targeted pharmaceutical therapies. Our lead diagnostic product is the LuCED® lung test - a non-invasive sputum-based test that detects abnormal cells which indicate lung cancer and bronchial dysplasia. LuCED lung test utilizes the Cell-CT platform and is in development for the early detection of lung cancer, bronchial dysplasia and the assessment of indeterminate pulmonary nodules (IPN). The LuCED test includes CellGazer™ application, an imaging software tool under development to facilitate cytopathology diagnosis of abnormal cell images detected by the Cell-CT platform. Visit www.visiongate3d.com to learn more.
Amnio Technology is a company based out of 22510 N 18TH DR, PHOENIX, Arizona, United States.
Avazyme, Inc. a contract research solution provider, offering field and laboratory testing, product development, and expert consulting services to the agriculture and food industries. Avazyme’s comprehensive services include food safety analyses for contaminants, pathogens, allergens, food quality and nutrition analysis, genetic trait testing, product safety, FDA Menu Labeling, pesticide residues, mycotoxin analysis, specialized studies for regulatory submission data packages, and a full spectrum of testing for product safety and product quality related to Industrial Hemp. Avazyme provides fast and reliable answers to ensure product safety and high product quality for consumable food, feed, cosmetics, nutraceutical Avazyme also offers comprehensive laboratory and "in-brewery" services to craft breweries and local hops growers and maltsters. Most recently, Volker and his Avazyme team have been a strong supporter and testing partner for the fast-emerging Industrial Hemp Industry in North Carolina and the entire East Coast
Elex Biotech Inc is a drug discovery and development company focused on first-in-class new chemical entities (NCEs) for the treatment of arrhythmia and heart failure. Using rational drug design and an internally generated SAR database, the Company has generated ~200 NCEs that stabilize mutant or dysfunctional Ryanodine receptor type 2 (RyR2), the Ca release channel that regulates the strength and frequency of heart muscle contractions. Certain arrhythmias and heart failure share a common defect in Ca handling resulting from RyR2 dysfunction that is addressed by Elex Biotech’s compounds. Elex Biotech has demonstrated in vivo proof of concept in animal models of catecholaminergic polymorphic ventricular tachycardia (CPVT), an orphan disease estimated to cause 15% of unexplained sudden cardiac death in apparently healthy young people.
AURA Devices is making smart wearables with bioimpedance technology as the fundamental one. We're helping athletes to achieve their goals and push their limits beyond.
Calibre Scientific is a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. The Company is committed to pushing the boundaries of science and innovation through internal expertise combined with strategic acquisitions that help deliver a differentiated and comprehensive set of products, services and support to our customers. Calibre Scientific was founded in 2016 by assembling a portfolio of niche life science companies, across various key verticals, that have an unrivaled ability to address the unique challenges of their respective markets. Through a combination of acquisitions and organic growth, our global reach extends into over 175 countries, empowering customers all over the world. Headquartered in Holland, Ohio, Calibre Scientific continues to grow across a wide array of verticals and geographies, further diversifying its product offering and global footprint to laboratories around the world.
SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.
Geltor is the biodesign company that audaciously imagines and deeply explores all the possibilities that the tree of life has to offer. With customer benefit at the fore of each step of the creative process, Geltor has created the largest selection of designer proteins that are crafted with unparalleled biocompatibility and functionality. These proteins are 100% animal- and GMO-free, globally scalable, and sustainably cultivated. Geltor’s products are the result of endless curiosity and ceaseless optimization, clinically demonstrated for high performance.
Anodyne Nanotech, Inc. is a preclinical-stage biotech company developing differentiated, transdermal forms of high-value drugs. The company’s macroporous microneedle technology provides the first practical and cost-effective platform, Hero Patch, to deliver clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules (such as ibuprofen) for fast and sustained delivery. We pride ourselves on providing a painless experience for all of those involved in the production, delivery, and consumption of medicines.
We're on a mission to futureproof the joy of food, starting with the joy of pig!
We're Hiring! Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in cell & gene therapies and cell line development.
Torus Biosystems is developing the next generation of POC molecular diagnostics for syndromic infectious diseases based on the novel integration of qPCR and microarray technologies that enable detection and quantification of DNA in under 30 minutes. The Synestia™ System employs the syndromic testing approach, which is faster and more accurate than conventional methods, and delivers rapid, comprehensive, sample-to-answer solutions at the patient point of care in a compact and portable system that supports decentralized healthcare settings. Torus Biosystems was spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University in 2020 to develop and commercialize the proprietary DNA/RNA detection technology developed by Wyss Core Faculty member, Peng Yin, PhD, Professor, Department of Systems Biology, Harvard Medical School, and Wyss Alumnus David Zhang, PhD, Associate Professor of Bioengineering, Rice University. Learn more about how Torus Bio can help improve patient outcomes, combat antibiotic resistance, and promote antimicrobial stewardship in a wide range of ambulatory settings including Hospital Outpatient and Emergency Departments and Long-Term Care facilities. Visit the website at www.torus.bio and connect with on social media @Twitter and @LinkedIn.
